At 30 weeks postrandomization , mean HbA1c changes were noninferior for exenatide compared with lispro ( -1.13 and -1.10 % , respectively ) ; treatment differences were -0.04 ( 95 % CI -0.18 , 0.11 ) in per-protocol ( n = 510 ) and -0.03 ( 95 % CI -0.16 , 0.11 ) in intent-to-treat ( n = 627 ) populations .